Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Dec;10(12):2394-404.
doi: 10.1158/1535-7163.MCT-11-0525. Epub 2011 Oct 6.

Death receptor pathway activation and increase of ROS production by the triple epigenetic inhibitor UVI5008

Angela Nebbioso  1 , Raquel Pereira, Harshal Khanwalkar, Filomena Matarese, José García-Rodríguez, Marco Miceli, Colin Logie, Valerie Kedinger, Felicetto Ferrara, Hendrik G Stunnenberg, Angel R de Lera, Hinrich Gronemeyer, Lucia Altucci
Affiliations

Death receptor pathway activation and increase of ROS production by the triple epigenetic inhibitor UVI5008

Angela Nebbioso et al. Mol Cancer Ther. 2011 Dec.

Abstract

Deregulation of the epigenome is recognized as cause of cancer and epigenetic factors are receiving major attention as therapeutic targets; yet, the molecular mode of action of existing epi-drugs is largely elusive. Here, we report on the decryption of the mechanism of action of UVI5008, a novel epigenetic modifier, that inhibits histone deacetylases, sirtuins, and DNA methyltransferases. UVI5008 highly efficiently induces cancer cell-selective death in a variety of models and exerts its activities in several human tumor xenografts and genetic mouse models of human breast cancer in vivo. Its anticancer activity involves independent activation of death receptors and reactive oxygen species production. Importantly, UVI5008 action is not critically dependent on p53, Bcl-2 modifying factor, and/or TNF-related apoptosis-inducing ligand as cell death is efficiently induced in cells mutated or deficient for these factors limiting the risk of drug resistance development and maximizing its application spectrum. The simultaneous modulation of multiple (epigenetic) targets promises to open new avenues with unanticipated potential against cancer.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types

MeSH terms

LinkOut - more resources